The authors report a case of pleural tumor discovered in case of thoracic pain in a 72 year old woman. This lesion, discovered on chest X-Ray, developed in the left costo-vertebral groove and was seen as a homogeneous opacity, multilobate, well-defined. CT confirmed the pleural origin, showed a thickening of posterior pleural, a polylobate tumor well-defined on its lung side, non-invasive and of tissue density. Histopathological examination of the operative specimen showed it to be a thymoma with an exceptional localization.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Unusual outcome of treatment of thymoma with immunotherapy: case report.
Mediastinum
November 2024
Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Background: Thymoma is a rare mediastinal neoplasm originating from thymic epithelial cells, often associated with paraneoplastic syndromes. These syndromes can manifest as a range of autoimmune disorders, including myasthenia gravis, pure red cell aplasia, and aplastic anemia. Clinical trials involving the use of immune checkpoint inhibitors (ICIs) in thymoma have been complicated by a high incidence of immune-related adverse effects (irAEs).
View Article and Find Full Text PDFSurgical management of thymic tumors: a narrative review with focus on robotic-assisted surgery.
Mediastinum
November 2024
University of Bern, Bern, Switzerland.
Background And Objective: Thymic epithelial tumors, including thymomas and thymic carcinomas, represent the most common mediastinal tumors and account for up to 50% of all anterior mediastinal tumors. For early stages of these thymic tumors, complete resection of the entire thymus is the recommended treatment. The transition from open surgery to video-assisted thoracoscopic surgery (VATS) and recently to robotic-assisted thoracic surgery (RATS) has fundamentally altered the treatment of thymic tumors.
View Article and Find Full Text PDFManaging recurrent thymic epithelial tumors after resection: outcomes and role of re-resection.
Mediastinum
November 2024
Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Thymic epithelial tumors (TETs) are rare neoplasms that include thymomas, thymic carcinomas (TCs), and thymic neuroendocrine neoplasms (TNENs). These three tumor categories differ in aggressiveness, the incidence of recurrence after resection, the pattern of recurrence, and survival outcomes. Owing to the tumor's rarity, randomized trials have not been performed in the initial treatment setting.
View Article and Find Full Text PDFSpatial Distribution Patterns of Pleural Dissemination in Patients With Thymoma and Survival Analysis.
Can Respir J
December 2024
Department of Radiation Oncology, Tangdu Hospital, The Second Affiliated Hospital of Air Force Medical University, Xi'an, China.
Thymoma is a common malignancy with low incidence, and pleural metastases are common pattern of recurrence. It is necessary that the spatial location of pleural metastatic lesions be analyzed. This study aimed to analyze the spatial distribution patterns of pleural dissemination in patients with thymoma and evaluate the variables that influence the survival of pleural metastasis in this population.
View Article and Find Full Text PDFLong term outcomes from the early days of minimally invasive thymoma surgery for Myasthenia Gravis patients: a follow-up of 19 years.
Front Surg
November 2024
Department of Cardiovascular Surgery, School of Medicine, West Virginia University, Morgantown, WV, United States.
Background: Long-term survival outcomes are crucial for accurately determining the effectiveness of treatment in an indolent disease like thymoma. We aimed to analyze the clinical findings in terms of survival and relapse patterns with a median follow up of 105 months (8.7 years) in patients with thymoma and myasthenia gravis who underwent minimally invasive surgery between 2002 and 2015.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!